A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumors
In brief
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
Key facts
- Study ID
- NCT06907043
- Run by
- Eikon Therapeutics
- People needed
- 130
- Starts
- 2025-04-30
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2025-08-19
Who can join
Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sarah Cannon Research Institute at HealthOne — Denver, Colorado, United States (enrolling)
- Florida Cancer Center — Lake Mary, Florida, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- MD Anderson — Houston, Texas, United States (enrolling)
- NEXT Oncology — San Antonio, Texas, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- PASO Medical — Frankston, Victoria, Australia (enrolling)
- Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (enrolling)
- Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital) — Jinan, Shandong, China (enrolling)
- Fudan University Shanghai Cancer Center — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.